Characteristics of COVID-19 in Homeless Shelters : A Community-Based Surveillance Study.


Journal

Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 16 9 2020
medline: 29 1 2021
entrez: 15 9 2020
Statut: ppublish

Résumé

Homeless shelters are a high-risk setting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission because of crowding and shared hygiene facilities. To investigate SARS-CoV-2 case counts across several adult and family homeless shelters in a major metropolitan area. Cross-sectional, community-based surveillance study. (ClinicalTrials.gov: NCT04141917). 14 homeless shelters in King County, Washington. A total of 1434 study encounters were done in shelter residents and staff, regardless of symptoms. 2 strategies were used for SARS-CoV-2 testing: routine surveillance and contact tracing ("surge testing") events. The primary outcome measure was test positivity rate of SARS-CoV-2 infection at shelters, determined by dividing the number of positive cases by the total number of participant encounters, regardless of symptoms. Sociodemographic, clinical, and virologic variables were assessed as correlates of viral positivity. Among 1434 encounters, 29 (2% [95% CI, 1.4% to 2.9%]) cases of SARS-CoV-2 infection were detected across 5 shelters. Most ( Selection bias due to voluntary participation and a relatively small case count. Active surveillance and surge testing were used to detect multiple cases of asymptomatic and symptomatic SARS-CoV-2 infection in homeless shelters. The findings suggest an unmet need for routine viral testing outside of clinical settings for homeless populations. Gates Ventures.

Sections du résumé

BACKGROUND
Homeless shelters are a high-risk setting for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission because of crowding and shared hygiene facilities.
OBJECTIVE
To investigate SARS-CoV-2 case counts across several adult and family homeless shelters in a major metropolitan area.
DESIGN
Cross-sectional, community-based surveillance study. (ClinicalTrials.gov: NCT04141917).
SETTING
14 homeless shelters in King County, Washington.
PARTICIPANTS
A total of 1434 study encounters were done in shelter residents and staff, regardless of symptoms.
INTERVENTION
2 strategies were used for SARS-CoV-2 testing: routine surveillance and contact tracing ("surge testing") events.
MEASUREMENTS
The primary outcome measure was test positivity rate of SARS-CoV-2 infection at shelters, determined by dividing the number of positive cases by the total number of participant encounters, regardless of symptoms. Sociodemographic, clinical, and virologic variables were assessed as correlates of viral positivity.
RESULTS
Among 1434 encounters, 29 (2% [95% CI, 1.4% to 2.9%]) cases of SARS-CoV-2 infection were detected across 5 shelters. Most (
LIMITATION
Selection bias due to voluntary participation and a relatively small case count.
CONCLUSION
Active surveillance and surge testing were used to detect multiple cases of asymptomatic and symptomatic SARS-CoV-2 infection in homeless shelters. The findings suggest an unmet need for routine viral testing outside of clinical settings for homeless populations.
PRIMARY FUNDING SOURCE
Gates Ventures.

Identifiants

pubmed: 32931328
doi: 10.7326/M20-3799
pmc: PMC7517131
doi:

Banques de données

ClinicalTrials.gov
['NCT04141917']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-49

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007044
Pays : United States

Investigateurs

Helen Y Chu (HY)
Michael Boeckh (M)
Janet A Englund (JA)
Deborah A Nickerson (DA)
Lea M Starita (LM)
Trevor Bedford (T)
Elisabeth Brandstetter (E)
Peter D Han (PD)
Michael L Jackson (ML)
Denise McCulloch (D)
Julia Rogers (J)
Thomas R Sibley (TR)
Melissa Truong (M)
Michael Famulare (M)
Barry R Lutz (BR)
Mark J Rieder (MJ)
Matthew Thompson (M)
Jay Shendure (J)
Amanda Adler (A)
Roy Burstein (R)
Shari Cho (S)
Anne Emanuels (A)
Chris D Frazar (CD)
Rachel E Geyer (RE)
James Hadfield (J)
Jessica Heimonen (J)
Anahita Kiavand (A)
Ashley E Kim (AE)
Louise E Kimball (LE)
Jack Henry Kotnik (JH)
Kirsten Lacombe (K)
Jennifer K Logue (JK)
Victoria Lyon (V)
Jessica O’Hanlon (J)
Matthew Richardson (M)
Monica L Zigman Suchsland (ML)
Caitlin R Wolf (CR)
Weizhi Zhong (W)

Auteurs

Julia H Rogers (JH)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Amy C Link (AC)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Denise McCulloch (D)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Elisabeth Brandstetter (E)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Kira L Newman (KL)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Michael L Jackson (ML)

Kaiser Permanente Washington Health Research Institute, Seattle, Washington (M.L.J.).

James P Hughes (JP)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Janet A Englund (JA)

Seattle Children's Research Institute, University of Washington, Seattle, Washington (J.A.E.).

Michael Boeckh (M)

Fred Hutchinson Cancer Research Center, Seattle, Washington (M.B., M.I., T.R.S., K.F., J.L., T.B.).

Nancy Sugg (N)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Misja Ilcisin (M)

Fred Hutchinson Cancer Research Center, Seattle, Washington (M.B., M.I., T.R.S., K.F., J.L., T.B.).

Thomas R Sibley (TR)

Fred Hutchinson Cancer Research Center, Seattle, Washington (M.B., M.I., T.R.S., K.F., J.L., T.B.).

Kairsten Fay (K)

Fred Hutchinson Cancer Research Center, Seattle, Washington (M.B., M.I., T.R.S., K.F., J.L., T.B.).

Jover Lee (J)

Fred Hutchinson Cancer Research Center, Seattle, Washington (M.B., M.I., T.R.S., K.F., J.L., T.B.).

Peter Han (P)

University of Washington and Brotman Baty Institute for Precision Medicine, Seattle, Washington (P.H., M.T., L.M.S.).

Melissa Truong (M)

University of Washington and Brotman Baty Institute for Precision Medicine, Seattle, Washington (P.H., M.T., L.M.S.).

Matthew Richardson (M)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Deborah A Nickerson (DA)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Lea M Starita (LM)

University of Washington and Brotman Baty Institute for Precision Medicine, Seattle, Washington (P.H., M.T., L.M.S.).

Trevor Bedford (T)

Fred Hutchinson Cancer Research Center, Seattle, Washington (M.B., M.I., T.R.S., K.F., J.L., T.B.).

Helen Y Chu (HY)

University of Washington, Seattle, Washington (J.H.R., A.C.L., D.M., E.B., K.L.N., J.P.H., N.S., M.R., D.A.N., H.Y.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH